This study is for adults aged **40 to 80** with *Chronic Obstructive Pulmonary Disease (COPD)*, a lung condition causing breathing problems. This study focuses on people who have an *eosinophilic phenotype*, which means they have higher counts of a type of white blood cell called eosinophils. The study compares a new medicine called *lunsekimig* with a placebo (a substance with no active drug) to see if it's safe and works well. Participants get injections under the skin (subcutaneous) for 48 weeks.

The study has three parts: 1) Screening for up to 4 weeks, 2) Treatment for 48 weeks, and 3) Follow-up for 8 weeks. In total, it lasts up to 60 weeks.

• Participants must have COPD for at least a year and have been on certain COPD medications for 12 weeks.
• Participants should not have asthma or other serious lung diseases.
• Participants can't take certain drugs or have certain health problems.

This information helps decide if joining the study is right for you.